Biocare Medical, one of the San Francisco, CA-based providers of immunohistochemistry (IHC), and FISH purchased Empire Genomics, a Buffalo, NY-based supplier of molecular biomarkers.
The price of the deal was not disclosed.
In partnership, Biocare Medical and Empire Genomics will provide a broader range of solutions for those looking to study and diagnose cancer across the globe.
Empire Genomics is a provider of FISH and ISH with over 100,000 biomarkers. These biomarkers allow hospitals and research institutions to offer relevant clinical tests. The company allows research to transform into effective tools for research and clinical use worldwide. The broad product line comprises Fluorescence in situ hybridization (FISH) and Chromogenic in situ hybridization (CISH) probes specifically designed and optimized for specific diseases and regions or genes that span the Human and Mouse genomes.
The CEO is Luis de Luzuriaga; Biocare Medical offers solutions to cancer research and diagnostics offering reagents including tissue-preserving simultaneously Multiplex IHC antibody cocktails and detections, Customer Care, and a full suite of instruments for IHC molecular histology tests. Its reagents include primary antibodies, Multiplex IHC, and FISH probes to target specific indications.
Also, read Accolite Digital Acquires TeamTek Consulting
Biocare also has a range of polymer detections suitable for human, clinical, and animal research, offering extremely high sensitivity and low background. Biocare’s automated instrument platforms, intelliPATH, and ONCORE Pro are developed to meet the needs of every researcher for high-throughput diagnostics in clinical research to the various research needs.